Lung cancer is the leading cause of cancer death worldwide, causing 1.4 million deaths annually [1]. Patients with advanced stage nonsmall cell lung cancer (NSCLC) are usually managed with combinations of platinum-based chemotherapy and they have poor prognosis with a median survival of 8 months [2]. Chromosomal rearrangements and gene mutations that contribute to the constant activation of kinases play a crucial role in the process of carcinogenesis. During the past decade, knowledge gained from next-generation sequencing has radically affected lung cancer management and led to targeted therapies. To this end, the discovery of missing lung cancer driving mutations together with comprehensive understanding of the molecular basis of the dise...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
Discovery of tyrosine kinase inhibitor sensitizing mutations in lung cancer (LC) appears to be the m...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
Lung cancer is the leading cause of cancer death worldwide, causing 1.4 million deaths annually [1]....
Landmark studies on genetic alterations underlying NSCLC have led to tailored therapies http://ow.ly...
The advent of precision medicine has brought light to the treatment of non-small cell lung cancer (N...
Lung cancer is the leading cause of cancer death worldwide, with an overall 5 year survival rate of ...
Amanda L Richer,1 Jacqueline M Friel,1 Vashti M Carson,2 Landon J Inge,1 Timothy G Whitsett2 1Norton...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
Non-small-cell lung cancer (NSCLC) subtypes are driven by specific genetic aberrations. For reasons ...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
Oncogenic mutations in lung cancer further our knowledge about cancer initiation and progression, an...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
Discovery of tyrosine kinase inhibitor sensitizing mutations in lung cancer (LC) appears to be the m...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
Lung cancer is the leading cause of cancer death worldwide, causing 1.4 million deaths annually [1]....
Landmark studies on genetic alterations underlying NSCLC have led to tailored therapies http://ow.ly...
The advent of precision medicine has brought light to the treatment of non-small cell lung cancer (N...
Lung cancer is the leading cause of cancer death worldwide, with an overall 5 year survival rate of ...
Amanda L Richer,1 Jacqueline M Friel,1 Vashti M Carson,2 Landon J Inge,1 Timothy G Whitsett2 1Norton...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
Non-small-cell lung cancer (NSCLC) subtypes are driven by specific genetic aberrations. For reasons ...
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond c...
Oncogenic mutations in lung cancer further our knowledge about cancer initiation and progression, an...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...
Discovery of tyrosine kinase inhibitor sensitizing mutations in lung cancer (LC) appears to be the m...
In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one ...